Orthofix Medical Inc. $OFIX Shares Sold by AREX Capital Management LP

Key Points

• AREX Capital Management LP has decreased its stake in Orthofix Medical Inc. by 19% to 81,000 shares, making it the 9th largest position in their portfolio, valued at approximately $1.3 million.
• The company's stock price is currently $14.89, down 0.6%, with a market cap of $588 million and a P/E ratio of -4.70.
• Recently, several analysts have rated Orthofix Medical with a mix of ratings, resulting in an average target price of $21.50, indicating potential upside from its current trading price.

AREX Capital Management LP lowered its stake in shares of Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 19.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 81,000 shares of the medical device company's stock after selling 19,000 shares during the quarter. Orthofix Medical makes up about 2.7% of AREX Capital Management LP's holdings, making the stock its 9th biggest position. AREX Capital Management LP owned 0.21% of Orthofix Medical worth $1,321,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. PDT Partners LLC purchased a new position in shares of Orthofix Medical during the first quarter worth approximately $548,000. Cubist Systematic Strategies LLC grew its position in shares of Orthofix Medical by 161.9% during the first quarter. Cubist Systematic Strategies LLC now owns 78,220 shares of the medical device company's stock worth $1,276,000 after acquiring an additional 48,353 shares during the last quarter. Trexquant Investment LP grew its position in shares of Orthofix Medical by 8.7% during the first quarter. Trexquant Investment LP now owns 60,536 shares of the medical device company's stock worth $987,000 after acquiring an additional 4,856 shares during the last quarter. Gamco Investors INC. ET AL grew its position in shares of Orthofix Medical by 1.0% during the first quarter. Gamco Investors INC. ET AL now owns 157,100 shares of the medical device company's stock worth $2,562,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Keeley Teton Advisors LLC grew its position in shares of Orthofix Medical by 36.4% during the first quarter. Keeley Teton Advisors LLC now owns 83,657 shares of the medical device company's stock worth $1,364,000 after acquiring an additional 22,320 shares during the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. JMP Securities restated a "market perform" rating on shares of Orthofix Medical in a research report on Friday, June 6th. Barrington Research upgraded shares of Orthofix Medical to a "strong-buy" rating and set a $16.00 price objective on the stock in a research report on Monday, June 23rd. Finally, Wall Street Zen upgraded shares of Orthofix Medical from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $21.50.

Orthofix Medical Price Performance

Shares of NASDAQ OFIX traded up $0.05 during trading on Monday, hitting $14.60. 83,876 shares of the company were exchanged, compared to its average volume of 335,259. The company has a market cap of $576.59 million, a price-to-earnings ratio of -4.60 and a beta of 0.86. Orthofix Medical Inc. has a 1 year low of $10.24 and a 1 year high of $20.73. The firm's fifty day moving average price is $12.54 and its 200 day moving average price is $13.31. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.67 and a quick ratio of 1.50.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The medical device company reported ($0.36) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.40). The company had revenue of $203.12 million for the quarter, compared to analysts' expectations of $196.89 million. Orthofix Medical had a negative return on equity of 25.43% and a negative net margin of 15.29%. Orthofix Medical has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Orthofix Medical Inc. will post -2.81 earnings per share for the current fiscal year.

Insider Activity at Orthofix Medical

In other Orthofix Medical news, insider Aviva Mcpherron sold 3,728 shares of the business's stock in a transaction on Wednesday, June 18th. The shares were sold at an average price of $10.51, for a total transaction of $39,181.28. Following the sale, the insider directly owned 46,322 shares in the company, valued at approximately $486,844.22. The trade was a 7.45% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.30% of the company's stock.

Orthofix Medical Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.